These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22618270)

  • 21. Antibiotic non-susceptibility among Streptococcus pneumoniae and Haemophilus influenzae isolates identified in African cohorts: a meta-analysis of three decades of published studies.
    Ginsburg AS; Tinkham L; Riley K; Kay NA; Klugman KP; Gill CJ
    Int J Antimicrob Agents; 2013 Dec; 42(6):482-91. PubMed ID: 24139883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.
    Sunakawa K; Farrell DJ
    Ann Clin Microbiol Antimicrob; 2007 Aug; 6():7. PubMed ID: 17697316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Seasonal patterns and association of meteorological factors with infection caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in childhood community-acquired pneumonia in a tropical region.
    Borges IC; Andrade DC; Cardoso MA; Meinke A; Barral A; Käyhty H; Ruuskanen O; Nascimento-Carvalho CM
    Infect Dis (Lond); 2017 Feb; 49(2):147-150. PubMed ID: 27464260
    [No Abstract]   [Full Text] [Related]  

  • 24. Antibiotic susceptibility in Streptococcus pneumoniae, Haemophilus influenzae and Streptococcus pyogenes in Pakistan: a review of results from the Survey of Antibiotic Resistance (SOAR) 2002-15.
    Zafar A; Hasan R; Nizamuddin S; Mahmood N; Mukhtar S; Ali F; Morrissey I; Barker K; Torumkuney D
    J Antimicrob Chemother; 2016 May; 71 Suppl 1(Suppl 1):i103-9. PubMed ID: 27048578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical and bacteriological evaluation of ceftriaxone (CTRX) dosed once daily in children with community-acquired pneumonia].
    Toyonaga Y; Kanemura H; Kitano M; Mitsui Y; Ishihara T; Hoshiai M; Ohno R
    Jpn J Antibiot; 1999 Apr; 52(4):322-32. PubMed ID: 10396689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From the Centers for Disease Control and Prevention. Antibiotic resistance among nasopharyngeal isolates of Streptococcus pneumoniae and Haemophilus influenzae--Bangui, 1995.
    JAMA; 1997 Feb; 277(8):621. PubMed ID: 9039868
    [No Abstract]   [Full Text] [Related]  

  • 27. Antimicrobial therapy in community-acquired pneumonia among emergency patients in a university hospital in Japan.
    Kawai S; Ochi M; Nakagawa T; Goto H
    J Infect Chemother; 2004 Dec; 10(6):352-8. PubMed ID: 15614461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Pneumococcal Conjugate Vaccine on the Natural Antibodies and Antibody Responses Against Protein Antigens From Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Children With Community-acquired Pneumonia.
    Andrade DC; Borges IC; Adrian PV; Meinke A; Barral A; Ruuskanen O; Käyhty H; Nascimento-Carvalho CM
    Pediatr Infect Dis J; 2016 Jun; 35(6):683-9. PubMed ID: 26954601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical efficacy of clarithromycin delayed release dosage form in the treatment of community-acquired pneumonia].
    Iutanova NS
    Antibiot Khimioter; 2004; 49(3):17-21. PubMed ID: 15344392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
    Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS
    Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cefditoren and community-acquired lower respiratory tract infections (corrected)].
    Barberán J; Mensa J
    Rev Esp Quimioter; 2009 Sep; 22(3):144-50. PubMed ID: 19662548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
    Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
    J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan.
    Saito A; Kohno S; Matsushima T; Watanabe A; Oizumi K; Yamaguchi K; Oda H;
    J Infect Chemother; 2006 Apr; 12(2):63-9. PubMed ID: 16648944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical features of healthcare-associated pneumonia (HCAP) in a Japanese community hospital: comparisons among nursing home-acquired pneumonia (NHAP), HCAP other than NHAP, and community-acquired pneumonia.
    Umeki K; Tokimatsu I; Yasuda C; Iwata A; Yoshioka D; Ishii H; Shirai R; Kishi K; Hiramatsu K; Matsumoto B; Kadota J
    Respirology; 2011 Jul; 16(5):856-61. PubMed ID: 21545370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bacterial Pathogens Associated with Community acquired Pneumonia : Authors Reply.
    Saikia L
    Indian Pediatr; 2016 Aug; 53(8):749-50. PubMed ID: 27567659
    [No Abstract]   [Full Text] [Related]  

  • 37. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.
    Trémolières F; de Kock F; Pluck N; Daniel R
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):447-53. PubMed ID: 9758291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia.
    Liu Y; Zhang Y; Wu J; Zhu D; Sun S; Zhao L; Wang X; Liu H; Ren Z; Wang C; Xiu Q; Xiao Z; Cao Z; Cui S; Yang H; Liang Y; Chen P; Lv Y; Hu C; Lv X; Liu S; Kuang J; Li J; Wang D; Chang L
    J Microbiol Immunol Infect; 2017 Dec; 50(6):811-820. PubMed ID: 26748734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of garenoxacin tablets on clinically diagnosed atypical pneumonia: postmarketing surveillance in Japan.
    Izumikawa K; Watanabe A; Miyashita N; Ishida T; Hosono H; Kushimoto S; Kohno S
    J Infect Chemother; 2014 Sep; 20(9):541-8. PubMed ID: 24934886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers.
    Nicodemo AC
    Braz J Infect Dis; 2003 Feb; 7(1):62-8. PubMed ID: 12807692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.